For Immediate Release
April 10, 2018
Los Angeles CA
DIGITAL ISSN: 2472-2448; PRINT ISSN: 0048-5764
Michael E. Thase, MD, Editor-in-Chief
James La Rossa Jr., Editorial Director
This is a unique call for scientific papers to be submitted for publication in Psychopharmacology Bulletin. Accepted manuscripts will be published in Bulletin and submitted for indexing within 90 days of submission. Bulletin publishes full-length research articles, review articles, brief reports, clinical case studies, commentary and letters.
Specifically, articles related to psychiatric research on lysergic acid diethylamide (LSD), methylenedioxymethamphetamine (MDMA), psilocybin, ketamine, and cannabis (cannabinoids), will be fast tracked. As is our custom, manuscripts submitted to the journal’s Negative and Failed Clinical Trial Reports, as well as the Bulletin’s new Epigenetics section, will be entitled to fast-track review, as will Original Research on a variety of psychiatric topics.
Psychopharmacology Bulletin is a peer-reviewed, multidisciplinary journal. It is a forum for researchers, medical practitioners and other professionals to record, publish, share ideas and research findings that serve to enhance the understanding of psychopharmacology. Psychopharmacology Bulletin is indexed in Index Medicus, EMBASE/Excerpta Medica, Psychological Abstracts, Current Contents, Science Citation Index, SCOPUS and Biological Abstracts under Psychopharmacol Bull.
All manuscripts will be peer review to ensure the maintenance of high standards and quality. Interested contributors are requested to follow the guidelines for preparation and submission of manuscripts as detailed in Author Guidelines at http://medworksmedia.com/author-guidelines/.
NOTE FROM THE PUBLISHER: Medworks Media has lowered the cost of yearly subscriptions to Psychopharmacology Bulletin for the remainder of 2018.
Thank you and good reading.